JP-CSPC@EC2602A(17388.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
JP-CSPC@EC2602A
17388.HK
News
View More

Morning Trend | CSPC PHARMA (1093.HK) Golden Cross Innovative Drug Theme Fermentation Strongly Leads the Rise

CSPC PHARMA (1093.HK) became a target for pharmaceutical funds early yesterday morning, performing strongly throughout the day and reaching a new high for the period. Positive news emerged that the company's innovative drugs are expected to be included in the medical insurance system, directly igniting the enthusiasm for bullish positions in the pharmaceutical sector. During the trading session, there was a coordinated increase in volume and price, with major funds gathering to drive the stock to lead the industry. After the announcement, overseas institutions quickly increased their allocation to Hong Kong pharmaceutical leaders, and CSPC PHARMA received significant attention from mainstream funds in the short term. The sector's rise benefited from support from medical insurance policies and a short-term recovery in industry sentiment. From a technical perspective, the MACD showed a golden cross, with the 5-day moving average providing support, and the overall K-line exhibited a smooth upward trend. At one point, it surged to a high, but the divergence between bullish and bearish funds gradually narrowed, closing firmly above the key support zone. It is worth noting that the implementation of innovative drugs still has a cycle, and if the policy direction and industry sentiment reverse, major funds may take concentrated profits. The rotation of market mainline hotspots has intensified, and if negative sentiment re-emerges, there could be significant volatility to watch out for. The operational suggestion is to pay attention to major changes and announcements in the industry, maintain flexible positions, avoid blindly chasing prices, and guard against the expansion of short-term risks. The medium-term bullish trend is good, and further upward space is expected

Technical Forecast·
SH
520880
-0.38%
HK
01093
+0.95%
SZ
159992
+0.47%
Technical Forecast·
SH
520880
-0.38%
HK
01093
+0.95%
SZ
159992
+0.47%

New Drug Administration Implementation Regulations Released: Allowing Innovative Drugs to be Produced in Segments, Accelerating the Market Launch of Good Medicines

The State Council has announced the newly revised "Regulations for the Implementation of the Drug Administration Law," which will take effect on May 15, 2026. This is the first comprehensive revision of the regulations in over twenty years. The key points of the revision include: improving the drug registration system, establishing exclusive market periods for pediatric drugs and drugs for rare diseases for the first time (up to 2 years and 7 years respectively), clarifying four new drug expedited approval pathways; strengthening the responsibilities of online drug trading platforms and regulating online drug sales; allowing segmented commissioning of innovative drug production to optimize the industrial supply chain; and shifting the regulatory focus from enterprises to drug marketing authorization holders, enhancing lifecycle supervision

Wallstreetcn·
HK
01093
+0.95%
SZ
159506
-0.76%
SH
513120
-0.99%
Wallstreetcn·
HK
01093
+0.95%
SZ
159506
-0.76%
SH
513120
-0.99%

CSPC PHARMA granted over 46.46 million shares as rewards

CSPC PHARMA granted 46.4625 million restricted shares to 727 employees under the share award plan, accounting for approximately 0.4% of the total issued shares. Based on the closing price of 9.81 yuan, the amount involved is approximately 456 million yuan. The awarded shares will vest in three batches, with the number granted depending on the respective performance targets, with a deadline of December 31, 2028

AASTOCKS·
SH
520690
-0.69%
HK
01093
+0.95%
SZ
159506
-0.76%
AASTOCKS·
SH
520690
-0.69%
HK
01093
+0.95%
SZ
159506
-0.76%

CSPC Pharmaceutical Grants 46.5 Million Restricted Shares to 727 Employees

CSPC Pharmaceutical Group has granted 46.5 million restricted shares to 727 employees as part of its equity incentive scheme. This represents about 0.4% of its issued share capital, with shares vesting in three tranches from January 2027 to January 2029, contingent on performance targets. The company retains 61.6 million shares for future grants. The latest analyst rating for CSPC stock (HK:1093) is a Hold with a price target of HK$10.50. CSPC focuses on the research, development, and sale of pharmaceuticals in both domestic and international markets.

Tip Ranks·
HK
01093
+0.95%
Tip Ranks·
HK
01093
+0.95%

CSPC PHARMA's subsidiary, CSPC Innovation, reported a loss of at least 170 million RMB last year

CSPC PHARMA's subsidiary, CSPC Innovation, issued a profit warning, expecting a loss of between 170 million and 250 million RMB for the fiscal year 2025, compared to a profit of 53.73 million RMB in the previous year. The reasons for the loss include an increase in R&D expenses to approximately 1 billion RMB, the acquisition of a minority stake in the controlling subsidiary, Jushi Biotech, leading to a greater impact on net profit, and a decrease in the gross profit margin of the functional raw materials business

AASTOCKS·
HK
01093
+0.95%
AASTOCKS·
HK
01093
+0.95%
Posts
View More
© 2026 Longbridge｜Disclaimer